Health economic assessment of the ATAC trial comparing anastrozole versus tamoxifen in adjuvant treatment of postmenopausal hormone receptor positive early breast cancer

被引：3
|
作者：
Annemans, L
Moeremans, K
Lamarque, H
机构：
[1] State Univ Ghent, HEDM, Meise, Belgium
[2] Astrazeneca, Rueil Malmaison, France
来源：
VALUE IN HEALTH | 2003年 / 6卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)61604-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：625 / 625
页数：1
相关论文
共 50 条
  • [21] Pharmacoeconomic aspects of adjuvant early breast cancer treatment in postmenopausal women with anastrozole or tamoxifen: a Slovenian perspective
    Piskur, R.
    Sonc, M.
    Cufer, T.
    Borstnar, S.
    Mrhar, A.
    EJC SUPPLEMENTS, 2004, 2 (03): : 75 - 75
  • [22] Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole trial
    Boccardo, F
    Rubagotti, A
    Puntoni, M
    Guglielmini, P
    Amoroso, D
    Fini, A
    Paladini, G
    Mesiti, M
    Romeo, D
    Rinaldini, M
    Scali, S
    Porpiglia, M
    Benedetto, C
    Restuccia, N
    Buzzi, F
    Franchi, R
    Massidda, B
    Distante, V
    Amadori, D
    Sismondi, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 5138 - 5147
  • [23] An economic evaluation of anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer (EBC) from a US healthcare perspective
    Locker, GY
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 24S - 24S
  • [24] 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer-efficacy overview
    Buzdar, AU
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2003, 86 (3-5) : 399 - 403
  • [25] Cost-effectiveness of anastrozole versus tamoxifen for the treatment of post menopausal hormone-receptor positive Breast Cancer (BC) in the adjuvant setting in Brazil
    Fonseca, M.
    Araujo, G.
    Saad, E.
    VALUE IN HEALTH, 2007, 10 (03) : A125 - A125
  • [26] Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women:: a sub-protocol of the 'Arimidex™ and Tamoxifen Alone or in Combination' (ATAC) trial
    Baum, M
    Dowsett, M
    Coibion, M
    Bianco, AR
    Cuzick, J
    George, WD
    Gray, J
    Howell, A
    Houghton, J
    Williams, N
    Sloane, J
    Tobias, J
    Buzdar, A
    Anderson, MD
    Jackson, I
    Sahmoud, T
    Gallagher, J
    Webster, A
    Gangji, D
    Petrakova, K
    Konopasek, B
    Mares, P
    Vodvarka, P
    Alcazar, A
    Campos, O
    Maxwell, A
    Goedhals
    Hacking, D
    Landers, G
    Smith, L
    Vorobiof, DA
    Werner, ID
    Blamey, R
    Coleman, R
    Grieve, RJ
    Hickish, T
    Howell, A
    Nicholls, JC
    Nicholson, S
    Raymond, S
    Salman, A
    Blum, J
    Clark, R
    Lyss, A
    Miletello, G
    Sternberg, J
    Forbes, J
    Coibion, M
    Nabholtz, JM
    Guastalla, JP
    BRITISH JOURNAL OF CANCER, 2001, 85 (03) : 317 - 324
  • [27] Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial
    British Journal of Cancer, 2001, 85 : 317 - 324
  • [28] Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Long term results of the Italian Tamoxifen Anastrozole trial
    Boccardo, F.
    Guglielmini, P.
    Bordonaro, R.
    Fini, A.
    Massidda, B.
    Porpiglia, M.
    Roagna, R.
    Serra, P.
    Orzalesi, L.
    Ucci, G.
    Rubagotti, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (07) : 1546 - 1554
  • [29] The ATAC ('Arimidex' Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PMI) women
    Tobias, JS
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S92 - S92
  • [30] Cost-effectiveness of anastrozole versus tamoxifen as adjuvant therapy in early breast cancer (EBC) - a German health economic analysis
    Lux, M. P.
    Benedict, A.
    Buchholz, S.
    Woeckel, A.
    Harbeck, N.
    Kreienberg, R.
    Kaufmann, M.
    Beckmann, M. W.
    Jonat, W.
    Hadji, P.
    Distler, W.
    Raab, G.
    Tesch, H.
    Weyers, G.
    Schneeweiss, A.
    Possinger, K.
    CANCER RESEARCH, 2009, 69 (02) : 380S - 380S
12345